Clinical Impact of Natural Killer Group 2D Receptor Expression and That of Its Ligand in Ovarian Carcinomas: A Retrospective Study

키워드

참고문헌 (36)

1. Morvan MG, "NK cells and cancer : you can teach innate cells new tricks", Nat Rev Cancer, 16, pp.7~19 (2016)
2. Bauer S, "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA", Science, 285, pp.727~729 (1999)
3. Girardi M, "Regulation of cutaneous malignancy by γδ T cells", Science, 294, pp.605~609 (2001)
4. Cosman D, "ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor", Immunity, 14, pp.123~133 (2001)
5. Yamamoto K, "Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line(CaCo-2)", Biochim Biophys Acta, 1526, pp.10~12 (2001)
6. Mamessier E, "Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition", Cancer Res, 71, pp.6621~6632 (2011)
7. Peng YP, "Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction", BMC Cancer, 14, pp.738~ (2014)
8. Cai X, "Control of tumor initiation by NKG2D naturally expressed on ovarian cancer cells", Neoplasia, 19, pp.471~482 (2017)
9. Diefenbach A, "The innate immune response to tumors and its role in the induction of T-cell immunity", Immunol Rev, 188, pp.9~21 (2002)
10. van den Broek MF, "The role of perforin in infections and tumour surveillance", Exp Physiol, 85, pp.681~685 (2000)
11. Wu Y, "Natural killer cells as a double-edged sword in cancer immunotherapy : a comprehensive review from cytokine therapy to adoptive cell immunotherapy", Pharmacol Res, 155, pp.104691~ (2020)
12. Rezvani K, "The application of natural killer cell immunotherapy for the treatment of cancer", Front Immunol, 6, pp.578~ (2015)
13. Rosen DB, "A Structural basis for the association of DAP12 with mouse, but not human, NKG2D", J Immunol, 173, pp.2470~2478 (2004)
14. Groh V, "Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis", Proc Natl Acad Sci U S A, 100, pp.9452~9457 (2003)
15. Vivier E, "Lymphocyte activation via NKG2D:towards a new paradigm in immune recognition?", Curr Opin Immunol, 14, pp.306~311 (2002)
16. Xuan XY, "Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma", Cancer Gene Ther, 22, pp.368~374 (2015)
17. Diefenbach A, "Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity", Nature, 413, pp.165~171 (2001)
18. Smyth MJ, "NKG2D function protects the host from tumor initiation", J Exp Med, 202, pp.583~588 (2005)
19. Chen J, "Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer", Ther Clin Risk Manag, 12, pp.11~18 (2015)
20. Weiss-Steider B, "Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells", J Exp Clin Cancer Res, 30, pp.37~ (2011)
21. Castriconi R, "Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors : consequences for the NKmediated killing of dendritic cells", Proc Natl Acad Sci U S A, 100, pp.4120~4125 (2003)
22. Krockenberger M, "Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D", J Immunol, 180, pp.7338~7348 (2008)
23. Becker JC, "Immunesuppressive properties of the tumor microenvironment", Cancer Immunol Immunother, 62, pp.1137~1148 (2013)
24. Pogge von Strandmann E, "NKp30 and its ligands : emerging players in tumor immune evasion from natural killer cells", Ann Transl Med, 3, pp.314~ (2015)
25. Duan S, "Natural killer group 2D receptor and its ligands in cancer immune escape", Mol Cancer, 18, pp.29~ (2019)
26. Frazao A, "NKG2D", NKG2-ligand pathway offers new oppor-tunities in cancer treatment, 2019, pp.10, 661~
27. Conejo-Garcia JR, "Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28-antitumor T cells", Cancer Res, 64, pp.2175~2182 (2004)
28. Poggi A, "Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by transretinoic acid", Cancer Res, 64, pp.9172~9179 (2004)
29. Sutherland CL, "ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15", Blood, 108, pp.1313~1319 (2006)
30. Li K, "Clinical significance of the NKG2D ligands, MICA", B and ULBP2 in ovarian cancer : high expression of ULBP2 is an indicator of poor prognosis, 2009, pp.58, 641~652
31. Kegasawa T, "Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients", Biochem Biophys Res Commun, 517, pp.84~88 (2019)
32. Denkert C, "Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer : a pooled analysis of 3771 patients treated with neoadjuvant therapy", Lancet Oncol, 19, pp.40~50 (2018)
33. Pernot S, "Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance", Gastric Cancer, 23, pp.73~81 (2020)
34. Semeraro M, "Clinical impact of the NKp30", B7-H6 axis in highrisk neuroblastoma patients, 2015, pp.7, 283~
35. Pasero C, "Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity", Cancer Res, 76, pp.2153~2165 (2016)
36. Lowry LE, "Potentiation of natural killer cells for cancer immunotherapy : a review of literature", Front Immunol, 8, pp.1061~ (2017)

관련 논문AI추천